Xbrane Biopharma Valuation
| XBRANE Stock | SEK 0.18 0.01 5.26% |
Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Xbrane Biopharma prevalent Real Value cannot be determined due to lack of data. The last-minute price of Xbrane Biopharma is kr0.18. Our model calculates the value of Xbrane Biopharma from examining the company fundamentals such as Operating Margin of (4.61) %, shares outstanding of 27.51 M, and Return On Asset of -0.13 as well as analyzing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Xbrane Biopharma's price fluctuation is out of control at this time. Calculation of the real value of Xbrane Biopharma is based on 3 months time horizon. Increasing Xbrane Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Xbrane Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Xbrane Stock. However, Xbrane Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.18 | Real 0.0 | Hype 0.0 | Naive 0.17 |
The real value of Xbrane Stock, also known as its intrinsic value, is the underlying worth of Xbrane Biopharma Company, which is reflected in its stock price. It is based on Xbrane Biopharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Xbrane Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Xbrane Biopharma AB helps investors to forecast how Xbrane stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Xbrane Biopharma more accurately as focusing exclusively on Xbrane Biopharma's fundamentals will not take into account other important factors: Xbrane Biopharma Total Value Analysis
Xbrane Biopharma AB is at this time projected to have takeover price of 2.32 B with market capitalization of 2.74 B, debt of 36.48 M, and cash on hands of 44.32 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Xbrane Biopharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.32 B | 2.74 B | 36.48 M | 44.32 M |
Xbrane Biopharma Investor Information
About 35.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 7.14. Xbrane Biopharma had not issued any dividends in recent years. Based on the key measurements obtained from Xbrane Biopharma's financial statements, Xbrane Biopharma AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Xbrane Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Xbrane Biopharma has an asset utilization ratio of 1.68 percent. This suggests that the Company is making kr0.0168 for each dollar of assets. An increasing asset utilization means that Xbrane Biopharma AB is more efficient with each dollar of assets it utilizes for everyday operations.Xbrane Biopharma Ownership Allocation
Xbrane Biopharma AB retains a total of 27.51 Million outstanding shares. Xbrane Biopharma owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.Xbrane Biopharma Profitability Analysis
The company reported the revenue of 11.53 M. Net Loss for the year was (188.38 M) with loss before overhead, payroll, taxes, and interest of (18.27 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Xbrane Biopharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Xbrane Biopharma and how it compares across the competition.
About Xbrane Biopharma Valuation
The stock valuation mechanism determines Xbrane Biopharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Xbrane Biopharma. We calculate exposure to Xbrane Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Xbrane Biopharma's related companies.Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 35 people.
8 Steps to conduct Xbrane Biopharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Xbrane Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Xbrane Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Xbrane Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Xbrane Biopharma's revenue streams: Identify Xbrane Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Xbrane Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Xbrane Biopharma's growth potential: Evaluate Xbrane Biopharma's management, business model, and growth potential.
- Determine Xbrane Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Xbrane Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Xbrane Stock analysis
When running Xbrane Biopharma's price analysis, check to measure Xbrane Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xbrane Biopharma is operating at the current time. Most of Xbrane Biopharma's value examination focuses on studying past and present price action to predict the probability of Xbrane Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xbrane Biopharma's price. Additionally, you may evaluate how the addition of Xbrane Biopharma to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |